Equillium announces preclinical data from new orally deliverable multi-cytokine inhibitor in presentation at the 18th annual peptide therapeutics symposium

La jolla, calif.--(business wire)---- $eq--equillium inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced a presentation at the 18th annual peptide therapeutics symposium highlighting eq302, a second generation orally deliverable multi-cytokine inhibitor in development to target il-15 and il-21. the symposium, bringing together leaders in peptide research from academia and industry to fo.
EQ Ratings Summary
EQ Quant Ranking